Can Xenon Pharmaceuticals cover its short-term obligations?

Its current ratio is 27.79 — current assets exceed current liabilities.

Where does Xenon Pharmaceuticals's balance sheet data come from?

Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Xenon Pharmaceuticals XENE Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$199.16M+39.6%	$142.71M-4.0%	$148.64M+160%	$57.24M-67.4%
Short-term investments	$349.72M-27.8%	$484.19M-1.1%	$489.44M-8.5%	$534.85M+42.2%
Prepaid expenses and other current assets	$10.39M+50.8%	$6.89M+14.7%	$6.01M-16.9%	$7.23M+61.2%
Total current assets	$560.65M-11.7%	$635.26M-1.5%	$644.96M+7.4%	$600.3M+7.4%
Property and equipment, net	$8.72M-15.1%	$10.28M+6.5%	$9.65M+48.5%	$6.5M+45.5%
Operating lease right-of-use assets	$6.63M-16.5%	$7.94M-13.6%	$9.19M-11.7%	$10.41M+29.2%
Deferred tax assets	$46.54M+293%	$11.85M+473%	$2.07M+34.3%	$1.54M-34.0%
Total assets	$633.16M-20.7%	$798.14M-17.3%	$964.8M+27.9%	$754.15M+31.8%
Accounts payable	$40.26M+17.6%	$34.22M+31.8%	$25.97M+16.9%	$22.21M+61.9%
Operating lease liabilities, current	$1.53M+11.9%	$1.37M+5.4%	$1.3M+166%	$488K-19.3%
Total current liabilities	$41.79M+17.4%	$35.59M+30.5%	$27.27M+20.1%	$22.7M+58.5%
Operating lease liabilities, non-current	$6.41M-16.1%	$7.65M-20.4%	$9.6M-3.4%	$9.95M+30.0%
Operating Lease Liabilities (Total)	$7.94M-11.9%	$9.02M-17.3%	$10.9M+4.5%	$10.44M+26.4%
Other non-current liabilities	$3.2M—	$0—	——	——
Total liabilities	$51.4M+18.9%	$43.24M+17.2%	$36.88M+12.9%	$32.65M+48.6%
Common stock	$1.6B+9.7%	$1.46B+1.4%	$1.44B+34.9%	$1.07B+36.0%
Additional paid-in capital	$228.23M+14.6%	$199.15M+27.0%	$156.76M+10.3%	$142.11M+20.9%
Retained earnings	-$1.25B-38.5%	-$899.47M-35.2%	-$665.14M-37.8%	-$482.75M-35.1%
Accumulated other comprehensive income (loss)	$335K+121%	-$1.61M-1,994%	-$77K+97.4%	-$3M-203%
Total stockholders' equity	$581.76M-22.9%	$754.9M-18.6%	$927.92M+28.6%	$721.5M+31.2%
Total liabilities and stockholders' equity	$633.16M-20.7%	$798.14M-17.3%	$964.8M+27.9%	$754.15M+31.8%
Short- term Investments	$349.72M-27.8%	$484.19M-1.1%	$489.44M-8.5%	$534.85M+42.2%
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$1.37M-6.7%	$1.47M—	——	——
Other Receivables	$1.37M-6.7%	$1.47M—	——	——
Net Investment in Lease	$6.63M-16.5%	$7.94M-13.6%	$9.19M-11.7%	$10.41M+29.2%
Deferred tax assets	$12.86M+33.1%	$9.67M+1,105%	$802K+57.6%	$509K+9.5%
Operating lease right-of-use assets	$6.63M-16.5%	$7.94M-13.6%	$9.19M-11.7%	$10.41M+29.2%
Operating Lease Right-of-Use Assets in Other Assets	$6.63M-16.5%	$7.94M-13.6%	$9.19M-11.7%	$10.41M+29.2%
Accounts payable and other current liabilities (Note 11)	$40.26M+17.6%	$34.22M+31.8%	$25.97M+16.9%	$22.21M+61.9%
Total debt	$7.94M-11.9%	$9.02M-17.3%	$10.9M+4.5%	$10.44M+26.4%
Additional paid-in capital	$228.23M+14.6%	$199.15M+27.0%	$156.76M+10.3%	$142.11M+20.9%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1.6B+9.7%	$1.46B+1.4%	$1.44B+34.9%	$1.07B+36.0%
Prepaid ship and debits	$7.15M-4.6%	$7.5M+1.4%	$7.4M-4.6%	$7.75M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Xenon Pharmaceuticals cover its short-term obligations?: Its current ratio is 27.79 — current assets exceed current liabilities.
Where does Xenon Pharmaceuticals's balance sheet data come from?: Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.